Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial

被引：1
|
作者：
Vernieri, C. [1 ]
Ligorio, F. [1 ]
Dieci, M. V. [2 ]
Lambertini, M. [3 ]
De Angelis, C. [4 ]
Iorfida, M. [5 ]
Botticelli, A. [6 ]
Strina, C. [7 ]
Vingiani, A. [8 ]
Provenzano, L. [1 ]
Bianchi, G. V. [1 ]
Folli, S. [9 ]
Generali, D.
Zambelli, A. [10 ]
de Placido, S. [4 ]
Del Mastr, L. [3 ]
Guarneri, V. [2 ]
Capri, G. [1 ]
Pruneri, G. [8 ]
De Braud, F. G. M. [1 ]
机构：
[1] Fdn IRCCS, Ist Nazl Tumori, Med Oncol & Hematol Dept, Milan, Italy
[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[3] IRCCS AOU San Martino, Dept Med Oncol, Ist Nazl Ric Cancro, IST, Genoa, Italy
[4] Azienda Osped Univ Federico II, Dept Clin Med & Surg, Naples, Italy
[5] European Inst Oncol, IEO, Div Med Senol, Milan, Italy
[6] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy
[7] ASST Cremona, Multidisciplinary Unit Breast Pathol & Translat, Cremona, Italy
[8] Fdn IRCCS, Ist Nazl Tumori, Dept Adv Diagnost, Milan, Italy
[9] Fdn IRCCS, Ist Nazl Tumori, Breast Unit, Milan, Italy
[10] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2829
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
352TiP
引用
收藏
页码：S322 / S323
页数：2
相关论文
共 50 条
  • [31] Phase 1/2 trial of the oncolytic virus, talimogene laherparpvec, in combination with neoadjuvant chemotherapy in stage II/III triple negative breast cancer
    Soliman, Hatem H.
    Hogue, Deanna
    Han, Hyo
    Lee, Catherine
    Ismail-Khan, Roohi
    Khong, Hung
    Niell, Bethany
    Czerniecki, Brian
    CANCER RESEARCH, 2018, 78 (04)
  • [32] Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)
    Sharma, Priyanka
    Kimler, Bruce F.
    O'Dea, Anne
    Nye, Lauren
    Wang, Yen Y.
    Yoder, Rachel
    Staley, Joshua M.
    Prochaska, Lindsey
    Wagner, Jamie
    Amin, Amanda L.
    Larson, Kelsey
    Balanoff, Christa
    Elia, Manana
    Crane, Gregory
    Madhusudhana, Sheshadri
    Hoffmann, Marc
    Sheehan, Maureen
    Rodriguez, Roberto
    Finke, Karissa
    Shah, Rajvi
    Satelli, Deepti
    Shrestha, Anuj
    Beck, Larry
    McKittrick, Richard
    Pluenneke, Robert
    Raja, Vinay
    Beeki, Venkatadri
    Corum, Larry
    Heldstab, Jaimie
    LaFaver, Stephanie
    Prager, Micki
    Phadnis, Milind
    Mudaranthakam, Dinesh Pal
    Jensen, Roy A.
    Godwin, Andrew K.
    Salgado, Roberto
    Mehta, Kathan
    Khan, Qamar
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 975 - 982
  • [33] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
  • [34] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
  • [35] Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer
    Sherry, Alexander D.
    von Eyben, Rie
    Newman, Neil B.
    Gutkin, Paulina
    Mayer, Ingrid
    Horst, Kathleen
    Chakravarthy, A. Bapsi
    Rafat, Marjan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (01): : 268 - 276
  • [36] A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
    Von Minckwitz, Gunter
    Schneeweiss, Andreas
    Salat, Christoph
    Rezai, Mahdi
    Zahm, Dirk Michael
    Klare, Peter
    Blohmer, Jens U.
    Tesch, Hans
    Khandan, Fariba
    Jud, Sebastian
    Jackisch, Christian
    Mehta, Keyur
    Loibl, Sibylle
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Wang, Chengzheng
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Lu, Zhenduo
    Li, Lianfang
    Sun, Xianfu
    Zhang, Chongjian
    Yue, Xiayu
    Xia, Qingxin
    Zhang, He
    Yan, Min
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [38] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Chengzheng Wang
    Zhenzhen Liu
    Xiuchun Chen
    Jianghua Qiao
    Zhenduo Lu
    Lianfang Li
    Xianfu Sun
    Chongjian Zhang
    Xiayu Yue
    Qingxin Xia
    He Zhang
    Min Yan
    Nature Communications, 14 (1)
  • [39] A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer
    Bellon, Jennifer R.
    Chen, Yu-Hui
    Rees, Rebecca
    Taghian, Alphonse G.
    Wong, Julia S.
    Punglia, Rinaa S.
    Shiloh, Ron Y.
    Warren, Laura E. G.
    Krishnan, Monica S.
    Phillips, John
    Pretz, Jennifer
    Jimenez, Rachel
    Macausland, Stephanie
    Pashtan, Itai
    Andrews, Chelsea
    Isakoff, Steven J.
    Winer, Eric P.
    Tolaney, Sara M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (01): : 45 - 52
  • [40] Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis
    Wang, Huibo
    Zhang, Nana
    Sun, Qi
    Zhao, Ziqi
    Pang, Hui
    Huang, Xiatian
    Zhang, Ruifeng
    Kang, Wenli
    Shan, Ming
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (06)
12345